Jazz Pharmaceuticals Plc Stock Cash Flow From Operations
| J7Z Stock | EUR 116.85 1.15 0.97% |
Jazz Pharmaceuticals plc fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.
Jazz |
Jazz Pharmaceuticals plc Company Cash Flow From Operations Analysis
Jazz Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Jazz Pharmaceuticals Cash Flow From Operations | 778.51 M |
Most of Jazz Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Jazz Pharmaceuticals plc has 778.51 M in Cash Flow From Operations. This is 47.65% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The cash flow from operations for all Germany stocks is 19.84% higher than that of the company.
Jazz Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.Jazz Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Jazz Fundamentals
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X | |||
| Price To Sales | 2.60 X | |||
| Revenue | 3.09 B | |||
| Gross Profit | 2.88 B | |||
| EBITDA | 718.41 M | |||
| Net Income | (329.67 M) | |||
| Cash And Equivalents | 833.95 M | |||
| Cash Per Share | 14.72 X | |||
| Total Debt | 6.02 B | |||
| Debt To Equity | 64.50 % | |||
| Current Ratio | 3.15 X | |||
| Book Value Per Share | 43.65 X | |||
| Cash Flow From Operations | 778.51 M | |||
| Earnings Per Share | (0.26) X | |||
| Price To Earnings To Growth | 3.86 X | |||
| Target Price | 208.5 | |||
| Number Of Employees | 3.2 K | |||
| Beta | 0.71 | |||
| Market Capitalization | 8.38 B | |||
| Total Asset | 12.3 B | |||
| Z Score | 0.6 | |||
| Net Asset | 12.3 B |
About Jazz Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .